We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution.
- Authors
Rogers, R. Kevin; Hiatt, William R.; Patel, Manesh R.; Shishehbor, Mehdi H.; White, Robin; Khan, Naeem D.; Bhalla, Narinder P.; Jones, W. Schuyler; Low Wang, Cecilia C.
- Abstract
There is limited evidence to guide clinical decision-making for antiplatelet therapy in peripheral artery disease (PAD) in the setting of lower extremity endovascular treatment. The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study (TI-PAD) evaluated the role of ticagrelor versus aspirin as monotherapy in the management of patients following lower extremity endovascular revascularization. The trial failed to recruit the targeted number of patients, likely due to aspects of the design including the lack of option for dual antiplatelet therapy, and inability to identify suitable patients at study sites. In response, the protocol underwent amendments, but these changes did not adequately stimulate recruitment, and thus TI-PAD was prematurely terminated. This article describes the rationale for TI-PAD and challenges in trial design, subject recruitment and trial operations to better inform the conduct of future trials in PAD revascularization.ClinicalTrials.gov Identifier: NCT02227368
- Subjects
PLATELET aggregation inhibitors; PERIPHERAL vascular disease treatment; MYOCARDIAL revascularization; DECISION making in clinical medicine; CLINICAL trials
- Publication
Vascular Medicine, 2018, Vol 23, Issue 6, p513
- ISSN
1358-863X
- Publication type
Article
- DOI
10.1177/1358863X18760996